胰高血糖素样肽-1与骨质疏松

糖尿病性骨质疏松发病率高、易致骨折,严重威胁老年人的健康.胰高血糖素样肽-1是由肠道L细胞分泌的一种重要的肠促胰岛素,近年来研究发现,其不仅具有降糖作用,而且表现出独立于胰岛素和甲状旁腺激素的促进骨形成作用,并通过降钙素间接抑制骨吸收,同时抑制骨髓间充质干细胞在早期向脂肪细胞分化,在糖尿病骨质疏松的发生、发展中发挥重要作用.     

胰高血糖素样肽-1受体激动剂对中枢神经系统的作用

胰高血糖素样肽-1受体(GLP-1R)激动剂通过GLP-1R刺激胰岛素分泌并改善胰岛细胞的状态,现已成为糖尿病领域研究热点.已证实GLP-1R在中枢神经系统有广泛表达,中枢应用GLP-1R激动剂后其可发挥保护神经细胞、调节食欲、调节认知功能等一系列作用,体现了其在中枢神经系统应用的潜质与价值.     

胰高血糖素样肽-1类似物改善肌肉萎缩的研究进展

胰高血糖素样肽-1(GLP-1)是由肠道L细胞分泌的一种肠促胰素,其主要功能是促进胰岛素分泌和抑制胰高血糖素分泌从而降低血糖,其制剂在临床上广泛用于糖尿病的治疗。近年来有研究发现,GLP-1类似物有改善肌肉萎缩的功能,该作用与抑制肌肉生长抑制素和肌萎缩因子表达、增强肌源性因子表达、改善骨骼肌微循环和胰岛素抵抗有关。     

胰高血糖素样肽-1与下丘脑食欲调节

下丘脑是神经内分泌中枢,也是食欲调节中枢.胰高血糖素样肽-1(GLP-1)是一种胃肠道激素,能够在下丘脑表达并对食欲中枢有调节作用.GLP-1作为一种厌食信号肽,通过促肾上腺皮质激素释放激素(CRH)通路、组胺神经元通路、神经肽和刺鼠相关蛋白(NPY/AgRP)以及前阿片黑皮质素原和可卡因-苯丙胺调节转录肽(POMC/CART)通路及AMP活化蛋白激酶(AMPK)介导的摄食负反馈信号通路参与调节摄食活动.针对GLP-1调节摄食作用机制的研究对肥胖、胰岛素抵抗和2型糖尿病的防治有重要的理论意义.     

人胰高血糖素样肽-1类似物:利拉鲁肽

胰高血糖素样肽-1(GLP-1)是一种肠促胰岛素,具有促进胰岛素释放、延缓胃排空、减低体重和降低食欲等生理作用.然而,大然的GLP-1很不稳定.可被二肽基肽酶-Ⅳ(DPP-Ⅳ)降解,半衰期仅为1～2 min.若采用天然GLP-1来降低血糖,需持续静脉输注或持续皮下注射,临床可行性较差.面对这种情况,人们不断探索,研发具有长效作用的人GLP-1类似物.本文着重论述此类药物的代表药物利托鲁肽(liraglutide).它的分子结构独特,通过和白蛋白结合,既保留了天然GLP-1的功效义延长了作用时间,可每日一次注射.临床应用中,它能安全、有效的控制糖代谢,改善胰岛β细胞功能,降低体重和收缩压.正是这种治疗的多效性,给2型糖尿病患者的治疗带来了新希单.     

胰高血糖素样肽-1与糖尿病心肌病变

胰高血糖素样肽-1(GLP-1)的生物学作用主要是促进胰岛素的分泌和合成、抑制胰高血糖素的分泌、增加胰岛β细胞的数量并抑制其凋亡等.研究显示,GLP-1有独特的心肌保护效应,如:抗心肌细胞凋亡、减轻微小血管病变、改善心肌能量代谢紊乱等.因此,进一步对GLP-1及其心肌保护作用机制做深入研究,可为治疗2型糖尿病及其心肌病...     

胰高血糖素样肽-1的心脏保护作用

胰高血糖素样肽-1( GLP-1)是由肠道内分泌L细胞分泌的一种重要的肠促胰岛素,具有促进胰岛素分泌、增加葡萄糖利用、降低血糖等生物学作用.研究显示,GLP-1具有明显的心脏保护作用,主要通过抑制心肌细胞凋亡、改善心肌收缩力、促进心肌葡萄糖的利用等直接或间接发挥其心脏保护作用,并逐渐应用于临床.进一步深入探讨GLP-1的心脏保护作用机制有助于临床上为心血管疾病患者提供新的治疗思路.     

胰高血糖素样肽-1及其类似物的降糖机制

胰高血糖素样肽-1(GLP-1)是由肠道L细胞分泌的肠促胰岛素,对调节机体葡萄糖稳态有重要作用.GLP-1与其受体结合后,促进葡萄糖依赖的胰岛素分泌、胰岛β细胞增殖和分化并抑制其凋亡、延迟胃排空、增加外周组织对胰岛素的敏感性,但不引起体重增加和低血糖,从而保护了胰岛β细胞功能.在疾病早期应用此类药物后,受损的β细胞功能和β细胞数量有逆转的可能.GLP-1及其类似物必将成为治疗糖尿病的一个新亮点.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

胰岛素为一具多种生物学效应的激素 ,在生理上保持营养物质代谢平衡 ,维持内环境恒定 ,调控细胞生长、增殖 ,保证正常的生长发育 ;在病理生理上 ,胰岛素分泌量过多或过少 ,对靶组织的敏感性加强或减弱都会造成病态 ,尤其是胰岛素抵抗及伴发的代谢综合征和 2型糖尿病已形成流行态势 ,严重危害中、老年人健康。胰岛素于 2 0世纪二十年代初问世 ,其生理作用的研究广泛而深入 ,但其确切的作用机制 ,在细胞、分子水平的生化过程多年不明。 5 0年后 ,1971年通过同位素标记的胰岛素与肝细胞膜制备物结合特性的研究 ,确定了胰岛素受体 (ＩＲ)的存在 …     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽-1及其类似物的降糖机制

Glucagon-like peptide-1 (GLP-1) is an insulin secretagogue that secreted by intestinal L-cells. After binding with its receptor, GLP-1 stimulates glucose-dependent insulin secretion, β-cell prolifera-tion and differentiation as well as inhibits its apeptosis, decelerates gastric emptying, improves insulin sensi-tivity of periphery tissue. The long-acting GLP-1 analogues decrease hyperglycemia safely without weight gain and hypoglycemia and protect the function of pancreatic islet beta-cell. Using GLP-1 analogues at early stages of the disease,impaired beta-cell function and possibly beta-cell mass appear to be reversible. These agents axe, therefore, considered new therapeutic agents for the treatment of patients with type 2 diabetes.     

胰高血糖素样肽1影响动脉粥样硬化的研究进展

胰高血糖素样肽1(GLP-1)是一种新型治疗2型糖尿病肠促胰液素,它可以在进食后血糖升高而刺激肠道分泌进而控制血糖。越来越多的研究表明,GLP-1可直接作用于心血管系统,例如可以影响内皮功能、炎症反应、血压、血脂代谢等。本文将对GLP-1类药物包括GLP-1类似物和二肽激肽酶4抑制剂影响动脉粥样硬化以及其潜在的机制进行综述。     

胰高血糖素样肽-1受体激动剂在心血管疾病中的研究进展

近年来新型降血糖药在心血管疾病治疗中获益显著。胰高血糖素样肽-1受体激动剂(GLP-1RA)是新一代降血糖药,除有较为明显的降糖作用外,还通过提高肠促胰岛素的活性在心血管系统中发挥保护作用。基础与临床研究表明,GLP-1RA具有抑制免疫反应、抑制平滑肌细胞增生和改善动脉粥样硬化形成等作用,在心血管临床研究中受到广泛关注。现对GLP-1RA在心血管疾病中直接或间接的影响进行综述,为临床防治提供理论基础。     

胰高血糖素样肽-1及其在心血管疾病中的作用

胰高血糖素样肽-1作为肠促胰岛素家族的一员,已被证实在2型糖尿病的治疗中起着重要作用,胰高血糖素样肽-1及其相关药物胰高血糖素样肽-1受体激动剂和二肽基从酶Ⅳ抑制剂等已成为糖尿病治疗药物中的新成员。在对胰高血糖素样肽-1的临床应用及深入研究后人们逐渐对其在糖尿病外的治疗作崩引起了重视,本文就胰高血糖素样肽-1及其相关药物在心血管疾病中的作用作一综述。